CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 25 enrolled
Drug / intervention
Travoprost ophthalmic solution, 0.004% (new formulation)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01658839
NCT01658839Phase 1Completed
CompareCT.gov

An Open-Label, Pharmacokinetic and Safety Study of Travoprost Ophthalmic Solution, 0.004% in Pediatric Glaucoma or Ocular Hypertension Patients

Alcon Research·interventional·Posted Aug 7, 2012·Updated Apr 1, 2016

In Brief

A Phase 1 clinical trial evaluating Travoprost ophthalmic solution, 0.004% (new formulation) for Glaucoma and Ocular Hypertension. Completed, enrolled 25 participants.

Detailed Summary

The purpose of this study was to assess the safety and describe the steady-state plasma pharmacokinetic (PK) profiles of Travoprost ophthalmic solution, 0.004% (new formulation) following a once daily administration for 7 days in pediatric glaucoma or ocular hypertension patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Ocular Hypertension
Countries--
Collaborators--

Timeline

Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 7, 2012
Enrollment StartJan 1, 2013
Primary CompletionJul 1, 2013
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 13.9 years ago

Interventions

Travoprost ophthalmic solution, 0.004% (new formulation)drug

Travoprost ophthalmic solution, 0.004%, new formulation